patients | PharmaTimes

Patients pleased?

John Pinching — Mon, 06 Jan 2025 09:00:58 +0000

Patients don’t take their medicines because they don’t want to

Leading with Purpose

John Pinching — Tue, 26 Mar 2024 12:08:57 +0000

AstraZeneca’s Andrea Mugan shares her unique perspectives on patients, experience, change and challenges

Clinical trial transformation funds for Aberdeen scientist

John Pinching — Wed, 29 Mar 2023 12:38:00 +0000

Dr Beatriz Goulao receives more than £500,000 to make trials more patient-focused

Research provides hope for patients with neurodegenerative disease

John Pinching — Wed, 16 Nov 2022 12:58:00 +0000

Findings highlight a potential new drug candidate that may delay disease progression

XBiotech enrols first patient in Natrunix study

John Pinching — Fri, 14 Oct 2022 12:40:00 +0000

Therapy involves patients with colorectal cancer at 20 medical centres

Huma and AstraZeneca collaborate to advance digital innovation

John Pinching — Wed, 23 Mar 2022 13:40:00 +0000

Digital-first patient care is a priority as the companies join forces to improve patients' lives

‘Lack of skills and distrust’ preventing patients from using internet

Anna Smith — Thu, 13 Feb 2020 11:53:00 +0000

A “lack of skills and a distrust of health information online” are two of the biggest barriers keeping patients from using the internet.

GP surgery closures hit ‘all-time-high’ last year

Anna Smith — Mon, 03 Jun 2019 12:55:00 +0000

The closures are directly affecting smaller practices, with nine out of 10 practices that closed serving fewer than 5,000 patients.

Centre of the pharmaverse

Selina McKee — Tue, 29 Jan 2019 08:28:00 +0000

An all-encompassing digital era has opened unique opportunities for industry to engage with patients meaningfully, while also creating a modernised healthcare landscape which yields trust and cooperation. For the most impactful communicators the future is now...

Empowering technology

PharmaTimes — Mon, 27 Feb 2017 15:44:00 +0000

How patient empowerment could change healthcare and pharma at the most fundamental level